In a first for the field, materials scientists from The Grainger College of Engineering at the University of Illinois ...

Think about how easily you recognize a friend in a dimly lit room. Your eyes capture light, while your brain filters out ...

"If it ain't broke, don't fix it," goes the old adage, which Rice University professor James Chappell completely ignored in a ...

Among patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT), atrial fibrillation (AF) is a frequent and high-risk complication, according to a study published ...

An Isle of Palms homeowner says a transformer that caught fire outside his home had shown warning signs for years — raising concerns about whether similar equip SC Democrats tout historic slate ...

Gilead Sciences is expanding its cell therapy pipeline and technological capabilities through the $7.8 billion acquisition of Arcellx, its partner in the development of a multiple myeloma treatment ...

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple sclerosis (MS), a chronic autoimmune disease that affects nearly one million ...

Never miss a story with The Brief, our free newsletter. Independent Texas reporting needs your support. Help us bring you and millions of others in-depth news and information. Will you join our ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...

A map of the immune cell landscape found in the bone marrow of patients with multiple myeloma could shed light on how the immune system interacts with cancerous plasma cells. It could also help ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to ...

Dec 10 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up ...